AllianceBernstein
ZNTL icon

AllianceBernstein’s Zentalis Pharmaceuticals ZNTL Stock Holding History

AllianceBernstein’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-109,538
Closed -$174K – 3350
2025
Q1 		$174K Hold
109,538
– – ﹤0.01% 2962
2024
Q4 		$332K Hold
109,538
– – ﹤0.01% 2817
2024
Q3 		$403K Sell
109,538
-1,200
-1% -$4.36K ﹤0.01% 2772
2024
Q2 		$453K Buy
110,738
+53,020
+92% +$592K ﹤0.01% 2722
2024
Q1 		$910K Hold
57,718
– – ﹤0.01% 2318
2023
Q4 		$874K Hold
57,718
– – ﹤0.01% 2341
2023
Q3 		$1.16M Sell
57,718
-1,263,717
-96% -$32.1M ﹤0.01% 2159
2023
Q2 		$37.3M Buy
1,321,435
+31,139
+2% +$747K 0.02% 662
2023
Q1 		$22.2M Sell
1,290,296
-75,202
-6% -$1.52M 0.01% 801
2022
Q4 		$27.5M Buy
1,365,498
+33,614
+3% +$723K 0.01% 747
2022
Q3 		$28.8M Sell
1,331,884
-22,579
-2% -$617K 0.01% 725
2022
Q2 		$38.1M Buy
1,354,463
+357,704
+36% +$9.48M 0.02% 653
2022
Q1 		$46M Buy
996,759
+69,822
+8% +$3.77M 0.02% 622
2021
Q4 		$77.9M Sell
926,937
-59,016
-6% -$4.57M 0.03% 504
2021
Q3 		$65.7M Buy
985,953
+45,125
+5% +$2.6M 0.03% 539
2021
Q2 		$50.1M Sell
940,828
-164,454
-15% -$8.81M 0.02% 622
2021
Q1 		$48M Buy
1,105,282
+270,834
+32% +$11.7M 0.02% 622
2020
Q4 		$43.3M Buy
834,448
+63,678
+8% +$2.87M 0.02% 624
2020
Q3 		$25.2M Buy
770,770
+272,498
+55% +$9.54M 0.01% 737
2020
Q2 		$23.9M Buy
+498,272
New +$19.1M 0.01% 712

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

AllianceBernstein's ZNTL Position: Q2 2025 in Review

AllianceBernstein sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 109,538 shares — an estimated $174K sold.

AllianceBernstein first reported a position in ZNTL in Q2 2020 and held it in 20 quarters. The position peaked at $77.9M in Q4 2021. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • AllianceBernstein reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 109,538 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $174K.
  • AllianceBernstein first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 20 quarters.
  • AllianceBernstein's Zentalis Pharmaceuticals position peaked at $77.9M in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.